Industry’s Lesson On Non-Inferiority Margins In Anti-Infective Trials: Use 10%

If industry is to learn anything from the three-day Anti-Infective Drugs Advisory Committee meeting on how to correctly use non-inferiority margins in trials, it is to adhere to the panel's recommendation of 10 percent (at least for now)